Health Care & Life Sciences » Biotechnology | Vectus Biosystems Ltd.

Vectus Biosystems Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
5.90
-
Cost of Goods Sold (COGS) incl. D&A
55.70
145.20
57.30
-
20.00
Gross Income
55.70
145.20
57.30
-
20.00
SG&A Expense
2,292.20
2,263.90
3,806.30
4,837.30
3,975.00
EBIT
2,347.90
2,409.10
3,863.60
4,859.60
3,995.00
Non Operating Income/Expense
115.60
-
169.60
0.50
-
Interest Expense
5.40
23.50
1.50
2.40
22.00
Pretax Income
2,212.90
2,429.60
3,959.70
4,818.60
4,016.00
Income Tax
730.80
773.80
748.30
1,024.40
1,429.00
Consolidated Net Income
1,482.10
1,655.90
3,211.30
3,794.30
2,587.00
Net Income
1,482.10
1,655.90
3,211.30
3,794.30
2,587.00
Net Income After Extraordinaries
1,482.10
1,655.90
3,211.30
3,794.30
2,587.00
Net Income Available to Common
1,482.10
1,655.90
3,211.30
3,794.30
2,587.00
EPS (Basic)
0.07
0.08
0.16
0.16
0.11
Basic Shares Outstanding
21,644.30
21,644.30
19,904.80
23,373.00
23,376.40
EPS (Diluted)
0.07
0.08
0.16
0.16
0.11
Diluted Shares Outstanding
21,644.30
21,644.30
19,904.80
23,373.00
23,376.40
EBITDA
2,292.20
2,263.90
3,806.30
4,831.40
3,975.00
Non-Operating Interest Income
24.80
3.00
75.10
42.90
1.00

About Vectus Biosystems

View Profile
Address
11 Primrose Avenue
Rosebery New South Wales (NSW) 2018
Australia
Employees -
Website http://www.vectusbiosystems.com.au
Updated 07/08/2019
Vectus Biosystems Ltd. is a drug discovery and development company. It is developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market namely, heart, kidney and liver disease. The company was founded by Karen Duggan on December 12, 2005 and is headquartered in Rosebery, Australia.